373 related articles for article (PubMed ID: 15816639)
1. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
[TBL] [Abstract][Full Text] [Related]
2. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
3. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer.
Ecke TH; Schlechte HH; Gunia S; Lenk SV; Loening SA
Urol Oncol; 2008; 26(5):470-3. PubMed ID: 18367114
[TBL] [Abstract][Full Text] [Related]
4. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; BrĂ¼nner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
5. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
6. TP53 gene mutations as an independent marker for urinary bladder cancer progression.
Ecke TH; Sachs MD; Lenk SV; Loening SA; Schlechte HH
Int J Mol Med; 2008 May; 21(5):655-61. PubMed ID: 18425359
[TBL] [Abstract][Full Text] [Related]
7. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
[TBL] [Abstract][Full Text] [Related]
8. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Casella R; Shariat SF; Monoski MA; Lerner SP
Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
[TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
10. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
13. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
14. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
[TBL] [Abstract][Full Text] [Related]
15. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
16. The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC).
Jumper C; Cobos E; Lox C
Anticancer Res; 2002; 22(4):2073-6. PubMed ID: 12174885
[TBL] [Abstract][Full Text] [Related]
17. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Span PN; Witjes JA; Grebenchtchikov N; Geurts-Moespot A; Moonen PM; Aalders TW; Vriesema JL; Kiemeney LA; Schalken JA; Sweep FC
BJU Int; 2008 Jul; 102(2):177-82. PubMed ID: 18336603
[TBL] [Abstract][Full Text] [Related]
18. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Champelovier P; Boucard N; Levacher G; Simon A; Seigneurin D; Praloran V
Urol Res; 2002 Oct; 30(5):301-9. PubMed ID: 12389118
[TBL] [Abstract][Full Text] [Related]
20. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]